Based on: Epilepsy — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 54 candidate interventions for epilepsy that are either approved medicines or have at least one registered clinical trial, built on 14 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 9 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Lacosamide — 6 registered trials · approved medicine · NCT02477839 NCT01484977 NCT00655551
- Levetiracetam — 2 registered trials · approved medicine · NCT06393309 NCT00643500
- topiramate — 2 registered trials · approved medicine · NCT00236730 NCT00236756
- Brivaracetam 2.5 mg — 2 registered trials · investigational · NCT00464269
- Emotion Memory Testing — 2 registered trials · investigational · NCT00486239
- eslicarbazepine — 1 registered trial · approved medicine · NCT01587339
- Ganaxolone — 1 registered trial · approved medicine · NCT04391569
- Oxcarbazepine — 1 registered trial · approved medicine · NCT00618046
- pregabalin — 1 registered trial · approved medicine · NCT01587339
- Rufinamide — 1 registered trial · approved medicine · NCT01405053
- zonisamide — 1 registered trial · approved medicine · NCT01587339
- Activity Tracker Group — 1 registered trial · investigational · NCT04357912
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in epilepsy and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: GABRA1, GABRA2, GABRB3, GRIN2A, GRIN2B, HCN1, KCNQ2, KCNQ3, KCNT1, MTOR, SCN1A, SCN2A, SCN8A, SLC6A1.
Which trials are registered?
- Advanced Space-time Resolved Techniques for Functional Neuroimaging at 7 Tesla MRI NCT07865546 · Recruiting · Phase NA · started 2024-10-16
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 NCT07563881 · Recruiting · Phase PHASE3 · started 2026-06-05
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures NCT05667142 · Recruiting · Phase PHASE3 · started 2023-02-14
- Evaluation and Treatment of Neurosurgical Disorders NCT00060541 · Recruiting · started 2003-06-04
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) NCT05716100 · Recruiting · Phase PHASE3 · started 2023-05-09
- Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database NCT02107989 · Recruiting · started 2014-03-11
- Spatial Memory and Temporal Lobe Epilepsy NCT06847152 · Completed · Phase NA · started 2025-02-26
- Investigating Epilepsy: Screening and Evaluation NCT03478852 · Recruiting · started 2018-03-28
- Impact of Epilepsy on the Brainstem Adenosine Pathway and Its Relation With Arousal and Respiratory Reactivity NCT07249034 · Recruiting · Phase NA · started 2026-10-01
- Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma NCT04553757 · Active Not Recruiting · started 2020-07-08
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.